MILFORD, Pa., Nov. 12, 2014 /PRNewswire/ -- Manzo Pharmaceuticals, Inc. (OTCPink:MNZO), today announced that Manzo's Tummy Relief™ for babies is now being sold at Alitons Pharmacy drug stores in New York and Pennsylvania, and at The Medicine Shoppe in Milford Pennsylvania. Kenneth Manzo, CEO, stated that this is the beginning stage of promoting his product and is seeking to have it sold by major chain stores. Although Mr. Manzo already had a relationship with Aliton's, he is also in talks with Walgreens and others to have the product sold through their online properties as well as their brick and mortar locations throughout the United States.
In addition, Manzo Pharmaceuticals today announced that they are nearing the end of a six month animal study, which tests Lacto-Freedom™, another of the company's products, and the results of the lactase producing probiotic, looks like it'll come to a close successfully. Successful results bring Manzo Pharmaceuticals, and partner, Celprogen, Inc., one step closer to human clinical trials, which will be part of the final preparations for the product's release.
As stated previously, the 6-month study is being conducted by Celprogen, Inc. using laboratory rats to test the new probiotic treatment. Lab rats are the ideal mammals to test because they are naturally lactose intolerant. After five months the rats given the treatment showed no negative side effects, even at very high doses. All doses from low to high concentration were very successful at colonizing the intestines and producing lactase, which enabled rats to digest lactose. This effect lasted for a full five months after the administration of the probiotic was discontinued. This long lasting residual effect is unique and is far superior to any other lactose intolerance treatment option currently on the market. Since approximately 25% of the population in the United States is lactose intolerant Manzo Pharmaceuticals and Celprogen are both confident that there will be a huge demand for this product.
Both Manzo pharmaceuticals, and Celprogen are very pleased with the results so far and eager to see the final result of how long the effects last. It's possible that Lacto-Freedom™ could subdue the symptoms of lactose intolerance for as much as the entire six months or beyond. Because of that possibility, the partners are beginning to seek out a company to do a human clinical trial.
The company has also recently convinced the DTCC to reopen the "Chill" issue and is in the process of fulfilling the DTCC's requests in order to lift the Chill that has been an obstacle in gaining large volume and liquidity for several years. Mr. Manzo is very confident that the DTC requirements will be met easily, and the company will update the shareholders as soon as it has news regarding its status. All efforts are being made to make Manzo Pharmaceuticals a huge success.
About Manzo Pharmaceuticals, Inc.
Manzo Pharmaceuticals, is a specialty pharmaceutical company engaged in the research, development, and testing of patented and non-patented solutions and remedies. Most notably is a patented probiotic for people who suffer from Lactose Intolerance, and a natural remedy for colic in babies. For more information follow the company on twitter at @manzopharma, and visit: www.manzopharma.com.
DISCLAIMER: This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential" and similar expressions. These statements reflect the Company's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information catered in this Press Release including such forward-looking statements.
SOURCE Manzo Pharmaceuticals, Inc.